CRISPR

CRISPR1-adora2ab

ID
ZDB-CRISPR-200116-1
Name
CRISPR1-adora2ab
Previous Names
None
Target
Sequence
5' - GATGGTGACGGCAAATGGAA - 3'
ZFIN BLAST NCBI BLAST Ensembl UCSC BLAT
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Genome Build: GRCz11Chromosome: 21
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
uva6 adora2ab
uva7 adora2ab
uva9 adora2ab
1 - 3 of 3
Expression
Gene expression in Wild Types + CRISPR1-adora2ab
No data available
Phenotype
Phenotype resulting from CRISPR1-adora2ab
No data available
Phenotype of all Fish created by or utilizing CRISPR1-adora2ab
Phenotype Fish Conditions Figures
peripheral nervous system oligodendrocyte increased amount, abnormal adora2abuva6/uva6; vu19Tg chemical treatment by environment: adenosine A2A receptor antagonist Fig. 4 with image from Fontenas et al., 2019
peripheral nervous system oligodendrocyte mislocalised, abnormal adora2abuva6/uva6; vu19Tg chemical treatment by environment: adenosine A2A receptor antagonist Fig. 4 with image from Fontenas et al., 2019
peripheral nervous system oligodendrocyte mislocalised, abnormal adora2abuva7/uva7; vu19Tg chemical treatment by environment: adenosine A2A receptor antagonist Fig. 4 with image from Fontenas et al., 2019
peripheral nervous system oligodendrocyte increased amount, abnormal adora2abuva7/uva7; vu19Tg chemical treatment by environment: adenosine A2A receptor antagonist Fig. 4 with image from Fontenas et al., 2019
peripheral nervous system oligodendrocyte increased amount, abnormal adora2abuva9/uva9; vu19Tg chemical treatment by environment: adenosine A2A receptor antagonist Fig. 4 with image from Fontenas et al., 2019
1 - 5 of 6 Show all
Citations
TSV
1 - 1 of 1
Show
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.